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Abstract
Background: Downstream of Ras, the serine/threonine kinase B-raf has been reported to be mutated,
among other carcinomas, in a substantial subset of primary melanomas with a preponderance of mutations
within the kinase domain including the activating V599E and V599K transitions.
Methods: We here investigated a representative series of 60 resection specimens of cutaneous and
subcutaneous melanoma metastases for the presence of mutations within the activation segment (exon
15) of the B-raf  kinase domain by polymerase chain reaction (PCR) and single-strand conformation
polymorphism (SSCP) gel electrophoresis.
Results: Sequencing of cloned PCR-SSCP amplicons resulted in 24 (40%) samples harbouring somatic
mutations which is not exceeding the mutation frequency in recently investigated primary melanomas. The
activating mutation T1796A was present in 24/60 (40%) resection specimens, followed in frequency by the
oncogenic g1795A mutation in 8/60 (13%) cases. As to the B-raf protein sequence, the acidic amino acid
transitions V599E and V599K were predicted in 19/60 (32%) and 6/60 (10%) cases, resepectively, but were
not associated with enhanced risk for subsequent metastasis in patients' follow up. In comparison to the
primary melanomas that we recently investigated, the spectrum of predicted B-raf protein mutations
narrowed significantly in the cutaneous/subcutaneous metastases. Unexpectedly, V599 and V599E
mutations were absent in cutaneous/subcutaneous metastases derived from acrolentiginous melanomas as
preceding primary tumours.
Conclusion: During transition from primary melanomas towards cutaneous/subcutaneous metastases,
the spectrum of predicted B-raf mutations narrows significantly. Focusing on the V599E and V599K, these
oncogenic mutations are likely to affect melanocyte-specific pathways controlling proliferation and
differentiation.
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Background
Melanomas are one of the most aggressive of the skin can-
cers and have shown a dramatic increase in both inci-
dence and mortality over the past decades [1]. Several
genes implicated in the development of various malig-
nancies, among them the tumour suppressor genes p53,
CDKN2A and PTEN and the Ras oncogenes, have been
extensively studied in melanoma and found to be rarely
mutated in resection specimens [2]. Recently, the B-raf
oncogene has been reported to be mutated, among other
carcinomas, in a majority of melanoma cell lines [3,4].
Remarkably, all mutations were within the kinase
domain, with a single amino acid substitution (V599E)
accounting for 95% of B-raf mutations in melanoma cell
lines [3,4] and leading to constitutive kinase activity [3].
In preliminary series of primary melanomas, 5/9 [3] and
4/5 [5] of the resection specimens harboured this V599E
mutation, and only a single different mutation occurred
[3]. Investigating a representative series of 50 resection
specimens of primary cutaneous melanomas, we detected
12/50 cases (24%) to harbour this V599E transition [6].
As limited attention has been given to metastatic
melanoma clinical specimens yet [7,8], we decided to ana-
lyse a representative number of resection specimens for
the presence of mutations in the activation segment (exon
15) of the B-raf kinase domain in cutaneous/subcutane-
ous melanoma metastases. Applying polymerase chain
reaction (PCR) and single-strand conformation polymor-
phism (SSCP) gel electrophoresis, followed by DNA clon-
ing and sequencing, we here describe B-raf kinase domain
mutations in a substantial subset of cutaneous/subcutane-
ous melanoma metastases, the oncogenic T1796A substi-
tution being the most frequent followed by the
neighboured g1795A transition.
Methods
Isolation of genomic DNA from paraffin embedded tissues
Total cellular DNA was extracted from paraffin embedded
tissues of 60 melanoma cutaneous and subcutaneous
metastases from 60 different patients from which
melanoma primary tumours of the skin had been excised
(previous primary tumours: 16 superficial spreading
melanomas, 8 nodular melanomas, 8 acrolentiginous
melanomas, 4 lentiginous melanoma, 18 melanomas not
further classified, 4 no specification, 2 no primary
melanoma). Using archival tissues for this study from pre-
vious patients' therapeutic surgery, there were no objec-
tions raised by the local ethics committee. DNA was
isolated from both tumour and surrounding skin tissues
by microdissection. Slides with 15 µm tissue sections were
incubated in xylene for 30 min and in a series of 100%,
80%, 60%, 40% ethanol and in aqua, 10 s each, at room
temperature. Tissue was scratched from the slides under
microscope, put in tubes, and isolation of DNA was per-
formed using the QIAamp DNA Mini Kit (Qiagen, Valen-
cia, CA, USA) according to the manufacturer's
instructions. The quality of the isolated DNA was assessed
by agarose gel electrophoresis.
Polymerase chain reaction (PCR)
Prior to PCR-SSCP analysis of B-raf exon 15 in melano-
mas, a 184 base pair (bp) fragment of the human A-myb
gene was amplified by primers A-Myb-1 and A-Myb-2 to
ensure the DNA integrity of the genomic DNA samples as
well as the absence of major Taq polymerase inhibitors.
PCR was performed in a final volume of 25 µl containing
0.6 units proofreading FailSafe Taq DNA polymerase and
12.5 µl FailSafe PCR 2X PreMix F (Biozym, Oldendorf,
Germany), containing 100 mM Tris-HCl pH 8.3, 100 mM
KCl, 400 µM of each dNTP, supplemented by 0.25 µl of
each primer (100 pmol/µl). PCR conditions were: 95°C 2
min, 46 cycles of 95°C 30 sec, 58°C 30 sec, 72°C 30 sec,
followed by 72°C 7 min. All PCRs were performed on a
GeneAmp 2400 thermal cycler (Perkin Elmer, Norwalk,
CT, USA). PCR products were analysed by 1.5% agarose
gel electrophoresis.
To screen for mutations in the activation segment (exon
15) of the B-raf kinase domain, 100 ng of each melanoma
DNA sample were PCR amplified by primers B-raf-6998-
for and B-raf-70221-rev in 25 µl PCRs as described above.
5 µl aliquots of each reaction were electrophoresed on
1.5% agarose/ethidiumbromide gels using highly resolv-
ing NuSieve 3:1 agarose (Biozym). Positive controls were
generated by a primer-mediated PCR mutagenesis-based
protocol as described (Ruiz et al, 1997). Here, we incorpo-
rated a third longer primer, B-raf-70009-A-for or B-raf-
70006-T-for, into the PCR along with the two wild-type
primers B-raf-6998-for and B-raf-70221-rev. Longer mis-
matched primers (LMP) share the sequence of the wild-
type primers but also contain additional bases, which
include a mismatched base. Primer sequences according
to the database of the National Center for Biotechnology
Information (NCBI, Bethesda, MD, USA, http://
www.ncbi.nlm.nih.gov/BLAST) were: A-Myb-1, 5'-CAT
ggA ATg CCA ATT TAA Cg-3'; A-Myb-2, 5'-CAT CCC TAA
gTT CgC TgC C-3' (gene database accession number
X66087); B-raf-6998-for, 5'-ggC CAA AAA TTT AAT Cag
Tgg A-3' (identical with primer sequence exon-15-rev
according to [3]); B-raf-70221-rev, 5'-TCA TAA TgC TTg
CTC TgA TAg gA-3' (identical with primer sequence exon-
15-for according to [3]; gene database accession number
NM_004333); B-raf-70009-A-for, 5'-ggC CAA AAA TTA
AAT Cag Tgg A-3'; B-raf-70006-T-for, 5'-ggC CAA AAT TTT
AAT Cag Tgg A-3'.
SSCP gel electrophoresis
The amplified DNA was mixed with an equal volume of
formamide loading dye (94% formamide, 0.05% xyleneBMC Cancer 2005, 5:58 http://www.biomedcentral.com/1471-2407/5/58
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cyanol and 0.05% bromphenol blue), denatured at 95°C
for 5 min, chilled on ice for 1 min and loaded onto Gene
Excel 12.5/24 polyacrylamide gels (Pharmacia Biotech,
Freiburg, Germany). Following non-denaturing electro-
phoresis at 600 Volt, 25 mA, 15 W, 6°C for 80 min, DNA
fragments were stained by silver using the DNA silver
staining kit according to the manufacturer's protocol
(Pharmacia Biotech). DNA fragments that reproducibly
showed mobility shifts according to independent two-
repeated SSCP analyses were cut out from the acrylamide
gel and subjected to semi-nested PCRs performed with
primers B-raf-70023-for and B-raf-70221-rev using the
conditions described above. Sequence of primer B-raf-
70023-for was: 5'-ATA gCC TCA ATT CTT ACC ATC C-3'.
Cloning of PCR amplicons and sequencing of plasmid 
inserts
Nested PCR products were then purified using the
QIAquick PCR purification kit (QIAGEN) and cloned into
pCRR2.1-TOPO vector (Invitrogen, NV Leek, Nether-
lands) according to the manufacturer's instructions.
Briefly, 10 ng of the secondary PCR product were ligated
into 10 ng vector and the ligation mixture was introduced
into competent TOP10 bacteria by heat shock. The library
was plated onto LB plates containing 50 µg/ml ampicillin.
Single bacterial transformants that appeared positive in
blue/white screening were picked randomly and grown in
2 ml LB medium containing 50 µg/ml ampicillin at 37°C
overnight. Following alkaline lysis of bacterial cultures
neutralized lysates were loaded onto silica-gel membranes
(QIAprep spin miniprep kit, Qiagen) and plasmid DNAs
were eluted in low-salt buffer.
Plasmid inserts were sequenced at a concentration of 50
ng/µl with a GeneAmp PCR system 9600 using ABI Prism
dGTP BigDye Terminator Ready Reaction Kits and the
AmpliTaq DNA polymerase FS according to the manufac-
turer's protocol (Perkin Elmer; Seqlab, Göttingen, Ger-
many). For sequencing B-raf exon 15 fragments from both
sides, M13 forward and M13 reverse primers were used.
PCRs consisted of 25 cycles including a denaturation step
at 96°C for 10 sec, a primer annealing step at 50°C for 5
sec and a chain elongation step at 60°C for 60 sec. Cycle
sequencing products were then ethanol precipitated, run
on a 4% polyacrylamide 7 M urea gel and analysed with
the ABI Prism 377 Genetic Analyser (Perkin-Elmer;
Seqlab). Primer sequences were: M13 forward primer, 5'-
CAA AAg ggT CAg TgC Tg-3'; M13 reverse primer, 5'-gTC
CTT TgT CgA TAC Tg-3'. The resulting sequences were
aligned to the known B-raf sequence in the NCBI database
(accession number NM_004333). The numbering began
with the start codon ATG, corresponding to nucleotide
positions 1–3. B-raf protein sequences predicted by the
cDNA sequences were compared with B-raf wild type pro-
tein sequence (NCBI accession number NP_004324)
using the BLASTX software at the NCBI.
Statistical Analysis
Fisher's exact test was used to assess clinical data and his-
tologic characteristics of the preceding primary melano-
mas as possible prognostic factors for the occurance of B-
raf exon 15 mutations and to compare the results in cuta-
neous/subcutaneous melanoma metastases with data very
recently reported from primary melanoma resection spec-
imens [6]. The exact Wilcoxon rank sum test [10] was
applied to test the hypothesis of B-raf exon 15 mutations
being associated with tumour thickness according to Bres-
low in the preceding primary melanomas. Length of time
between excision of primary melanomas and the occur-
ance of cutaneous/subcutaneous metastases which we
investigated was compared with length of time between
excision of the cutaneous/subcutaneous metastases that
we analysed and subsequent metastases by the exact Wil-
coxon signed rank test. For all statistical analyses the sta-
tistical software package R, version 1.7 [11], was used. All
statistical tests were 2-sided. An effect was considered sta-
tistically significant at P < 5%.
Results
Pattern of B-raf exon 15 mutations
Assessing the presence of amplifyable DNA by PCR ampli-
fication of a 184 bp human A-myb  gene fragment, 60
resection specimens of melanoma cutaneous/subcutane-
ous metastases were positive for both cancerous and
matched noncancerous tissues. Positive results in A-myb
PCR were in accordance with agarose gel electrophoresis
showing the integrity of the high molecular weight DNA.
These melanoma resections specimens were then ana-
lysed by PCR and SSCP gel electrophoresis for mutations
in exon 15 of the B-raf gene. 24/60 (40%) cases exhibited
SSCP patterns distinctly different obtained from corre-
sponding adjacent normal tissues (Figure 1). The total cel-
lular DNA samples amplified with elongated primers that
harboured mutations were identified as positive controls
in all PCR-SSCP analyses (data not shown).
Sequencing of cloned PCR-SSCP amplicons resulted in 24
positive melanoma samples harbouring a total of 44 DNA
point mutations of B-raf exon 15 (Table 1). The activating
mutation T1796A [3] was present in 24 (40%) of the 60
investigated melanoma metastases (Figure 2), followed in
frequency by the g1795A mutation in 8 cases (13%). Alto-
gether, 16 different B-raf  exon 15 mutations (T1749C,
g1757A, C1758A, T1760C, T1779C, T1787A, A1794T,
g1795A, T1796A, T1803g, A1810g, A1823g, g1824A,
A1830C, T1837C, T1847C) were detected in the 60 inves-
tigated cutaneous melanoma resection specimens. In all
melanomas, the mutations in neoplastic tissues wereBMC Cancer 2005, 5:58 http://www.biomedcentral.com/1471-2407/5/58
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shown to be somatic by cloning and sequencing of SSCP
gel bands from the corresponding normal tissues.
It is remarkable that CC to TT or C to T transitions, which
occur in the p53 gene in non-melanoma skin cancers fol-
lowing exposure to ultraviolet light [12-15] were not
detected in any of the investigated melanoma resection
specimens.
Predicted changes of the B-raf protein sequence
Next, the B-raf protein sequences predicted by the nucle-
otide sequences that we found were compared with the
known B-raf protein sequence (NCBI accession number
NP_004324) using the BLASTX software. All melanomas
harbouring  B-raf  point mutations were predicted to
exhibit alterations of the protein sequence (Table 1).
Within the kinase domain, the oncogenic V599E amino
acid substitution occurred in 19 of the 60 tested melano-
mas (32%), followed in frequency by V599K in 6/60
(10%) cases, both protein mutations occurring in two
separate DNA fragments from melanoma case 46 (Table
1). Valine at protein sequence position 599 was replaced
in all (100%) of the melanoma resection specimens posi-
tive for B-raf exon 15 mutations. No nonsense mutation
of B-raf exon 15 DNA, causing a predicted protein trunca-
tion, occurred in our analysis.
Altogether, 9 different B-raf exon 15 protein mutations
(D586N, L587P, F594L, V599E, V599K, S604G, E610D,
S613P, I616T) were detected in the 60 investigated cuta-
neous/subcutaneous melanoma resection specimens. In
comparison to the 16 different protein mutations very
recently described in 19/50 B-raf mutations bearing pri-
mary melanomas [6], a narrowing of the spectrum of pre-
dicted B-raf protein mutations is observed during
transition from primary melanomas towards cutaneous/
subcutaneous metastases (p = 0.04 upon Fisher's exact
test; estimated odds ratio 2.64, 95% confidence interval
0.97–7.63).
Applying Fishers's exact test, Clark's level of the primary
melanoma (p = 0.46 and p = 0.55, respectively), level of
UV irradiation of the preceding primary tumours (locali-
zation of the primary melanomas with chronic, intermit-
tent or none UV exposition, p = 0.72 and p = 0.54,
respectively) and type of subsequent metastasis (none,
cutaneous, lymph node, visceral; p = 0.52 and p = 0.75,
respectively) were no statistically significant prognostic
PCR-SSCP analysis of B-raf exon 15 in resection specimens from cutaneous/subcutaneous melanoma metastases Figure 1
PCR-SSCP analysis of B-raf exon 15 in resection specimens from cutaneous/subcutaneous melanoma metas-
tases. Cases 7, 23, and 54 exhibit different DNA fragment mobilities when compared to the respective normal tissues from 
patients. Suspecting these tumour specimens to harbour mutations, these samples were subjected to DNA sequencing.
melanoma case 23
normal tissue case 14
melanoma case 27
melanoma case 30
melanoma case 35
melanoma case 42
melanoma case 54
melanoma case 14
normal tissue case 35
normal tissue case 23
normal tissue case 30
normal tissue case 42
normal tissue case 54
normal tissue case 27
normal tissue case 9
melanoma case 9
normal tissue case 7
melanoma case 7BMC Cancer 2005, 5:58 http://www.biomedcentral.com/1471-2407/5/58
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factors for the occurence of valine substitution at B-raf
amino acid position 599 (V599) or for the detection of the
oncogenic V599E mutation, respectively. The occurence
of valine substitution at B-raf amino acid position 599
(V599) or the detection of the V599E mutation were not
associated with a change in the distribution of tumour
thickness according to Breslow of the prededing primary
melanomas (exact Wilcoxon rank sum test: p = 0.40 and p
= 0.46, respectively). Unexpectedly, the histologic diagno-
sis of acrolentiginous melanoma in the preceding primary
tumour (Fishers's exact test: p = 0.02 and 0.04, respec-
tively) was associated with the absence of V599 and
V599E in the cutaneous/subcutaneous metastases.
Table 1: B-raf exon 15 mutations in resection specimens of melanoma cutaneous/subcutaneous metastases. Predicted protein 
sequence alterations are listed together with the clinical course of the disease in patients' follow up. Distinct mutations in two different 
abnormal bands in SSCP gels are specified by two lines for one melanoma.
Case Previous primary 
(months before)
DNA mutations Predicted Protein changes Subsequent Metastasis 
(months later)
1 MM-2.7-IV (30 m) T1796A V599E LN (1 m)
g1757A D586N
7 NM-2.5-IV (11 m) T1796A V599E liver (simult)
A1810g S604G
12 SSM (18) T1796A V599E liver (74 m)
13 NM-2.1-V (50) T1796A V599E liver (2 m)
20 NM-4-IV (51) T1796A V599E none (74 m)
T1837C S613P
22 MM (19) T1796A V599E sc (7 m)
23 MM-1.9-III (37) g1795A, T1796A V599K lung, liver (simult)
24 MM-2.5-IV (84) T1796A V599E bone (simult)
28 no data g1795A, T1796A V599K no follow up
C1758A, T1760C, g1795A, T1796A V599K, L587P
29 NM-3.6-IV (13) g1795A, T1796A V599K liver (3 m)
32 no data g1795A, T1796A V599K no follow up
g1795A, T1796A, T1803G V599K
34 no data T1779C, T1796A F594L, V599E no follow up
37 SSM-1.8-IV (120) T1796A V599E sc (2 m)
T1796A, A1823g V599E
41 MM (144) T1796A V599E lung (simult)
43 SSM-1.8-IV (21) T1796A V599E lung (3 m)
44 MM (71) T1796A V599E lung (simult)
46 LMM-2.7-IV (53) T1796A V599E bone (20 m)
g1795A, T1796A V599K
47 MM-1.8-IV (126) T1796A V599E none (42 m)
T1787A, T1796A V599E
50 SSM-0.6-III (157) T1749C, T1796A V599E brain, bone (simult)
G1824A WT
53 no primary T1796A V599E bone (simult)
T1796A, T1847C V599E, I616T
54 LMM-III (290) T1796A V599E sc (8 m)
T1796A, A1794T V599E
55 MM-10-V (5) T1796A, A1830C V599E, E610D lung (22 m)
56 MM (1) T1796A V599E lung (1 m)
58 LMM-1.2-V (6) g1795A, T1796A V599K sc (12 m)
Abbreviations used in Table 1: A, adenine; C, cytosine; D, asparagin acid; E, glutamic acid; F, phenylalanine; G, glycine; g, guanine; I, isoleucine; 
K, lysine; L, leucine; LMM, lentiginous malignant melanoma; LN, lymph node; m, month(s); MM-2.7-IV, melanoma, not further classified, tumour 
thickness according to Breslow 2.7 mm, Clark's level IV; N, asparagine; NM, nodular melanoma; P, proline; S, serine; sc, subcutaneous; simult, 
simultaneous; SSM, superficial spreading melanoma; T, thymine; T1857A, change from thymine to adenine at nucleotide 1857 (according to NCBI 
accession number NM_004333, the start codon ATG corresponding to nucleotide positions 1–3); V, valine; V599E, substitution of valine to 
glutamic acid at codon 599 (according to NCBI accession number NP_004324.1); WT, wild type of protein sequence.BMC Cancer 2005, 5:58 http://www.biomedcentral.com/1471-2407/5/58
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Part of the DNA sequence of the activation segment of the B-raf kinase domain Figure 2
Part of the DNA sequence of the activation segment of the B-raf kinase domain. Representative melanoma resec-
tion specimens are shown which harbour missense mutations. In comparison to wild type DNA sequence (upper electrophe-
rogram, forward sequence on the left, reverse sequence on the right), melanoma cases 7, 23 and 54 exhibit nucleotide 
transitions, among them the activating T1796A mutation.
Reverse sequence Forward sequence
Wild type
Melanoma case 7
T1796A
Melanoma case 23
g1795A, T1796A
Melanoma case 54
A1794T, T1796ABMC Cancer 2005, 5:58 http://www.biomedcentral.com/1471-2407/5/58
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B-raf mutations and clinical outcome
56 of the 60 patients were seen in follow up examinations.
Following cutaneous/subcutaneous metastases, subse-
quent metastasis occurred in 55 patients including 11
cutaneous, 9 lymph node and 35 visceral decays (lung 15,
bone 7, liver 6, brain 6, kidney 1). The median follow up
period for all patients was 17 months (lower quartile 5.75
months; upper quartile 25 months).
Addressing the 11 patients with only subsequent cutane-
ous metastasis and the single patient which remained free
of disease for 50 months (case 18), the follow up period
of this subgroup was longer with a median of 22 months
(lower quartile 17.25 months; upper quartile 25.25
months). The time between excision of primary melano-
mas and the occurance of cutaneous/subcutaneous metas-
tases which we investigated (median 51 months; lower
quartile 20 months; upper quartile 111.5 months) was
longer in comparison to the length of time between exci-
sion of the cutaneous/subcutaneous metastases that we
analysed and subsequent metastasis during follow up
(exact Wilcoxon signed rank test: p < 0.001 ; estimated
median difference 49 months with 95% confidence inter-
val ranging from 29 months to 70.5 months). Following
a long period free of disease after excision of the primary
tumour, cutaneous/subcutaneous metastasis may there-
fore be regarded as a first indicator of melanoma progres-
sion, shortly followed by subsequent visceral metastasis in
most patients.
Looking at the 24 cutaneous/subcutaneous melanoma
metastases harbouring the oncogenic V599E or V599K
amino acid substitutions, 21 patients were seen in follow
up examinations and all of them developed subsequent
metastasis. In comparison, 35/36 patients with B-raf exon
15 wild type metastases were monitored in follow up
examinations from which 34 developed further metasta-
sis. A single patient (melanoma metastasis case 18)
remained free of tumour in a follow up interval of 50
months.
Comparing mutations of B-raf exon 15 in cutaneous/sub-
cutaneous metastases with those in primary melanomas
[6] by Fisher's exact test, no statistically significant differ-
ences in the proportion of mutations in general (p = 0.85;
odds ratio = 0.92, 95% confidence interval 0.39–2.13),
T1796A (p = 0.56; odds ratio = 0.77, 95% confidence
interval 0.33–1.81), V599 (p = 0.56; odds ratio = 0.77,
95% confidence interval 0.33–1.81), V599E (p = 0.40;
odds ratio = 0.68, 95% confidence interval 0.26–1.72)
and V599K (p = 0.77; odds ratio = 1.22, 95% confidence
interval 0.30–4.94) could be observed.
Discussion
Cancers arise owing to the accumulation of mutations in
critical genes that alter normal programmes of cell prolif-
eration, differentiation and death. One important path-
way mediating cellular responses to growth signals is the
RAS-RAF-mitogen-activated protein (MAP)-kinase kinase
(MEK)-extracellular signal-regulated kinase (ERK)-MAP
kinase cascade whose activation can be achieved by muta-
tion at various levels [16]. RAS is mutated to an oncogenic
form in about 15% of human cancer. In a mouse model
null for the tumour suppressor INK4a, melanoma initia-
tion and maintanance were dependent upon expression
of H-RasV12G [17]. Still, H-Ras as well as K-ras mutations
rarely occur in human cutaneous melanomas [18,19] and
are even less frequent in comparison to N-Ras which is
mutated in less than 15% of uncultured melanoma tissue
specimens [19-22]. Neither quantitative nor qualitative
alterations of ras-p21 expression were found to correlate
with tumour progression [20]. Downstream of Ras and
upstream of MEK lies B-raf, which is highly present in
neural cells and tissues [23-25]. This kinase belongs to the
Raf family of serine/threonine kinases regulated by bind-
ing RAS which is composed of the ubiquitously expressed
Raf-1 and by A-Raf and B-raf [16]. RAF proteins phospho-
rylate MEK1/2, which in turn phosphorylate ERK1/2. Very
recently,  B-raf  somatic missense mutations have been
reported in 59% of 34 melanoma cell lines [3]. All muta-
tions were within the kinase domain, with a single substi-
tution (V599E) accounting for 95% of all B-raf mutations
in the melanoma cell lines.
In preliminary series of primary melanomas, 5/9 [3] and
4/5 [5] of the specimens harboured this V599E mutation,
and only a single different mutation occurred in the B-raf
oncogene outside of exon 15 [3,7]. Investigating a repre-
sentative series of 50 resection specimens of primary cuta-
neous melanomas, we recently detected 12/50 cases
(24%) to harbour the V599E transition independent from
risk for further metastasis [6]. In contrast to cutaneous
melanoma, V599E was detected in none of 46 familial
melanomas [26], 21 multiple melanomas [26], 29 [27]
and 48 [28] uveal melanomas. In 80 melanoma families,
V599E was no germline mutation [29].
Addressing melanoma metastases, the V599E transition
has recently been reported for 83% of 12 [5] and 50% of
28 [7] lymph node and in 64% of 12 [5] and 52% of 27
[7] visceral melanoma metastases. Looking at cutaneous/
subcutaneous metastases, 63% of 29 cutaneous/subcutae-
nous cases were reported to harbour this oncogenic muta-
tion [5]. These reports are in line with our data, the
mutation rate in melanoma metastases similar to primary
melanomas [6] suggesting V599E and V599K as early
events in melanocyte transformation, possibly contribut-
ing to proliferation and survival, but not to metastaticBMC Cancer 2005, 5:58 http://www.biomedcentral.com/1471-2407/5/58
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spread. This postulate is supported by the finding of B-raf
exon 15 mutations in a major subset of nevi [5,30].
As a novel finding, we here describe the spectrum of pre-
dicted B-raf protein mutations narrowing significantly
during transition from primary melanomas towards cuta-
neous/subcutaneous metastases. Focusing on V599E and
V599K in cutaneous/subcutaneous metastases, these
oncogenic transitions are nonetheless not associated with
enhanced risk for subsequent further metastasis. As the B-
rafV599E  mutant possesses tenfold greater basal kinase
activity and induces focus formation in NIH3T3 cells 138
times more efficiently than does wild-type B-raf [3], rele-
vance of this alteration in the development of melanomas
is very likely. For the growth of cancer cell lines with the
V599E mutation, RAS function was not required any more
[3]. The V599E mutation is thought to mimic phosphor-
ylation of threonine 598 and serine 601 within the activa-
tion loop of B-raf at the plasma membrane, resulting in a
protein with high activity and leading to constitutive ERK
activation [31].
Whereas the missense mutation T1796A alone predicts
the activating amino acid substitution V599E within the
B-raf kinase domain, T1796A together with the g1795A
nucleotide transition predict another acidic amino acid
substitution, namely V599K with transforming activity in
NIH3T3 cells comparable to V599E transfectants [32]. As
a novel finding, we here describe the V599K mutation in
10% (6/60) of the tested cutaneous/subcutaneous metas-
tases which is identical to the recently reported frequency
of 10% (5/50) in primary melanomas [6]. In contrast to
our data, V599K has been detected by other investigators
in noticeable lower frequencies of 1% (1/77; [7]) and 3%
(2/60; [30]) of melanoma metastases which may be due
to higher sensitivity of the PCR-SSCP approach that we
applied when compared to direct sequencing of tumour
DNA samples.
As we found mutations within the activation segment
(exon 15) of the B-raf kinase domain in a total of 24
(40%) of all investigated metastatic resection specimens
which unexceptionally affected valine at protein sequence
position 599, this protein sequence position seems to be
a hot spot for alterations. The high frequency of B-raf
mutations in melanomas may be related to a principal
melanocyte-specific signalling pathway controlling prolif-
eration and differentiation: α -melanocyte stimulating-
hormone (α -MSH) and proopiomelanocortin-derived
peptides, secreted by keratinocytes, bind to the melano-
cortin receptor I on melanocytes, leading to increased pro-
liferation and melanogenesis in response to UVB
radiation [33]. This signalling cascade via stimulation
through G-protein coupled receptors (GPCRs) and upreg-
ulation of cyclic AMP (cAMP) does not require RAS but
also activates B-raf and subsequently ERK [34]. When acti-
vated, extracellular signal-regulated kinases (ERKs) trans-
locate to the nucleus where they regulate gene expression,
leading to cell proliferation. The activation of ERKs by
cAMP has been reported in a limited number of cell sys-
tems, including B16 melanoma [35].
Endothelin-1 (Et-1), a strong melanocyte mitogen
[36,37], is another candidate for signaling through B-raf.
Et-1, produced by keratinocytes and accentuated by expo-
sition of keratinocytes to UVB radiation, can activate the
MAP kinase pathway, although the role of B-raf in trans-
ducing this signal has not been demonstrated in melano-
cytes [38]. Besides α -MSH and Et-1, the RAS-RAF-MEK-
MAP kinase cascade is also activated by the growth factors
basic fibroblast growth factor [39] and stem cell factor
[40], leading to increased proliferation of cultured human
melanocytes.
That principal melanocyte-specific signalling pathways
controlling proliferation and differentiation operate
through activation of B-raf possibly explains the high fre-
quency of B-raf mutations in melanomas when compared
to colon (18% of 40 cell lines and 12% of 33 tumours) or
ovarian cancers (4% of 26 cell lines and 14% of 35
tumours, according to [3]), an exception being papillary
thyroid carcinomas with 69% (24/35 cases positive, [41])
and 36% (28/78 cases positive, [42]) of the investigated
cases, respectively. The attempt of inhibiting B-raf activity
in melanoma has been inspired by the demonstration that
the ERK1/2 inhibitor U0126 [43,44] decreases prolifera-
tion of melanoma cell lines bearing B-raf mutations [3].
Conclusion
Altogether, the serine/threonine kinase B-raf, involved in
the Ras-Raf-MEK-ERK-MAP kinase pathway of signal
transduction, harbours mutations of it's kinase domain in
40% of 60 melanoma metastatic resection specimens
which is not exceeding the mutation frequency in primary
melanomas [6] and which is not associated with
enhanced risk for subsequent further metastasis. The
oncogenic V599E and V599K transitions account for 79%
and 25% of these positive metastases, respectively, one
melanoma resection specimen (case 46) bearing both
mutations. Acrolentiginous melanoma as preceding pri-
mary tumour was associated with the absence of V599 and
V599E. During transition from primary melanomas
towards cutaneous/subcutaneous metastases, the
spectrum of predicted B-raf protein mutations narrows
significantly. The B-raf mutations that we detect in uncul-
tured primary melanoma samples are distinct from C to T
or CC to TT mutations associated with pyrimidine dimer
formation following UV radiation [12,13]. As B-raf altera-
tions possibly affect melanocyte-specific pathways con-
trolling proliferation and differentiation, inhibition of B-BMC Cancer 2005, 5:58 http://www.biomedcentral.com/1471-2407/5/58
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raf activity may be a future strategy in the treatment of
melanoma as is currently addressed in phase I and II stud-
ies [45].
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